Dario Altieri
Dario Carlo Altieri, M.D., is a researcher who works as director of The Wistar Institute Cancer Center in Philadelphia.[1] In 2015, he became the CEO of The Wistar Institute.[2]
His research has focused on Inhibitors of Apoptosis (IAP), a family of genes essential for proliferation and survival of cells. His work has identified survivin, one of these IAP genes, is over-produced in almost every human cancer, and his team is currently studying the biology of survivin and how it could be used to develop treatments for cancer.[3][4][5]
Altieri has also been involved in the development of gamitrinib, a Hsp90 inhibitor that was shown to disable the activity of mitochondria in cancerous cells.
In 2013, Altieri and his team received a $1.5 million grant from the Department of Defense to prepare the drug for human trials.[6][7] Prior to joining Wistar, Altieri was the founding chair of the Department of Cancer Biology at the University of Massachusetts Medical School. He also co-founded the Cancer Biology Training Consortium and the Pancreatic Cancer alliance in 2005.[8]
Select publications
- Chae, Y. C., Angelin, A., Lisanti, S., Kossenkow, A. A., Speicher, K. D., Wang, H., Powers, J. F., Tischler, A. S., Pacak, K., Fliedner, S., Michalek, R. D., Karoly, E. D., Wallace, D. C., Languino, L. R., Speicher, D. W. and Altieri, D. C. (2013) Landscape of the mitochondrial Hsp90 metabolome in tumors. Nature Commun. 4:2139.
- Caino, M. C., Chae, Y. C., Vaira, V., Ferrero, S., Nosotti, M., Martin, N. M., Weeraratna, A., O’Connell, M., Jernigan, D., Fatatis, A., Languino, L. R., Bosari, S., and Altieri, D. C. (2013) Metabolic stress regulates cytoskeletal dynamics and metastasis of cancer cells. J. Clin. Invest. 123:2907-2920.
- Chae, Y. C., Caino, M. C., Lisanti, S., Ghosh, J. C., Dohi, T., Danial, N. N., Villanueva, J., Ferrero, S., Vaira, V., Santambrogio, L., Bosari, S., Languino, L. R., Herlyn, M., and Altieri, D. C. (2012) Control of tumor bioenergetics and survival stress signaling by mitochondrial Hsp90s. Cancer Cell 22:331-344.
- Siegelin, M. D., Dohi, T., Raskett, C. M., Orlowsky, G. M., Powers, C. M., Gilbert, C. A., Ross, A. H., Plescia, J., and Altieri, D. C. (2011) Exploiting the mitochondrial unfolded protein response for cancer therapy in mice and human cells. J. Clin. Invest. 121:1349-1360.
- Mehrotra, S., Languino, L. R., Raskett, C. M., Mercurio, A. M., Dohi, T., andAltieri, D. C. (2010) IAP regulation of metastasis. Cancer Cell. 17:53-64.
References
- ↑ "Cancer Biologist Dario Altieri to Lead the Wistar Institute Cancer Center". The Wistar Institute. Retrieved 11 February 2014.
- ↑ "Dario C. Altieri: Chief Executive Officer of Wistar Institute". The University of Pennsylvania. Retrieved 2 March 2015.
- ↑ "Dario C. Altieri, M.D.". The Wistar Institute. Retrieved 28 January 2014.
- ↑ "Thrivin' (not just survivin') in Philadelphia". The Journal of Clinical Investigation. Retrieved 28 January 2014.
- ↑ "Emerging Research Fronts - 2009". ScienceWatch. Retrieved 11 February 2014.
- ↑ "Wistar Receives $1.5 Million Department of Defense Grant To Ready Potential Prostate Drug For Clinical Use". The Wistar Institute. Retrieved 28 January 2014.
- ↑ "Combinatorial Drugs Target Cancer Cell Mitochonndria". biotechdaily.com. Retrieved 11 February 2014.
- ↑ "Cancer Biologist Dario Altieri to Lead the Wistar Institute Cancer Center". The Wistar Institute. Retrieved 28 January 2014.